The QualityStocks Daily Thursday, December 8th, 2022

Today's Top 3 Investment Newsletters

The Stock Dork(PHVS) $11.4600 +356.57%

MarketClub Analysis(EXPR) $1.7700 +38.28%

Schaeffer's(CVNA) $4.9600 +29.50%

The QualityStocks Daily Stock List

Venus Acquisition (VENA)

We reported earlier on Venus Acquisition (VENA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Venus Acquisition Corporation (NASDAQ: VENA) operates as a blank check firm whose objective is to acquire assets and businesses through a reorganization, stock purchase, asset acquisition, capital stock exchange or a merger.

The firm has its headquarters in New York and was incorporated in 2018, on May 14th. It is incorporated as an exempted company in the Cayman Islands and its fiscal year ends on December 31.

While it is yet to identify any acquisition target, the firm’s efforts in identifying prospective target businesses aren’t limited to a specific geographic region, even though it intends to center on businesses that have a connection to the Asian Market.

The firm's CEO, who's also the president of CoAdna, a wavelength selective switch maker and its CFO, who also occupies the CEO position in Alum Developing, a Chinese alloy distributor, have decades of experience in the M&A sector.

The company recently launched its IPO, with Brookline Capital Markets acting as a joint bookrunner with Ladenburg Thalmann & Co Inc. acting as a book-running manager for the offering. The firm closed at 4,600,000 units at a price of $10 per unit, which helped rake in gross proceeds of $46,000,000. The firm’s market value is bound to grow to over $50 million soon, given the number of outside investors who bought stocks at its IPO launch and the experience of their management team.

Venus Acquisition (VENA), closed Thursday's trading session at $11.92, up 24.5559%, on 27,417 volume. The average volume for the last 3 months is 7.749M and the stock's 52-week low/high is $7.2742/$16.17.

Neurobo Pharmaceuticals (NRBO)

QualityStocks, The Stock Dork, MarketClub Analysis, MarketBeat, Zacks, The Online Investor, StockMarketWatch and InvestorPlace reported earlier on Neurobo Pharmaceuticals (NRBO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Neurobo Pharmaceuticals Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology firm that is engaged in the provision of therapies for cardio-metabolic and neurodegenerative ailments as well as the coronavirus.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2014, on October 30th. Prior to its name change, the firm was known as Gemphire Therapeutics Inc. It operates as part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm serves consumers in the U.S. and has 3 companies in its corporate family.

The company’s pipeline is made up of a drug formulation dubbed NB-02 indicated for the treatment of cognitive impairment and helps alter the progression of neurodegenerative ailments like Alzheimer’s; and a formulation dubbed NB-01 that targets neuropathic pain and is focused on treating painful diabetic neuropathy. In addition to this, the company also develops an oral niclosamide formulation known as ANA001, which recently conclude phase 2 clinical trials evaluating its effectiveness in treating moderate coronavirus infections. This is in addition to Gemcabene, which has been developed to treat dyslipidemia, which is a severe medical condition that grows the risk of life-threatening cardiovascular diseases. This formulation also focuses on orphan indications like SHTG (severe hypertriglyceridemia) and HoFH (homozygous familial hypercholestrerolemia)

The firm recently released its financial results for 2021’s first quarter, with its CEO noting that they were focused on value-creating milestones with their programs, which are bound to bring in more investments into the firm.

Neurobo Pharmaceuticals (NRBO), closed Thursday's trading session at $1.73, up 25.3623%, on 7,749,374 volume. The average volume for the last 3 months is 585,548 and the stock's 52-week low/high is $1.13/$63.85.

Venus Concept Inc. (VERO)

QualityStocks, MarketBeat, StreetInsider, StockMarketWatch and TradersPro reported earlier on Venus Concept Inc. (VERO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Venus Concept Inc. (NASDAQ: VERO) (FRA: ORR1) is a medical technology firm that is focused on the development, commercialization and delivery of non-invasive and minimally invasive medical aesthetic and hair restoration technologies.

The firm has its headquarters in Toronto, Canada and was incorporated in 2002, on November 22nd. It operates as part of the professional and commercial equipment and supplies merchant wholesalers’ industry. The firm has nine companies in its corporate family and serves consumers around the globe.

The enterprise’s product portfolio comprises of a dermabrasion device known as Venus Glow which improves skin appearance; a device used in non-invasive lipolysis of the flanks and abdomen in people with a BMI of 30 or less dubbed Venus Bliss; a non-invasive device used in general surgical and dermatologic procedures for non-invasive treatment of facial wrinkles and rhytides known as Venus Freeze Plus; and Venus Fiore, which is used to treat the mons pubis, labia skin tightening and the vaginal canal. It also provides a portable, advanced fractional RF system known as Venus Viva, for dermatological procedures which require ablation and skin resurfacing and a multi-application device used in cosmetic and aesthetic procedures called Venus Versa. In addition to this, the enterprise offers robotic systems dubbed Artas and ArtasiX, which help identify and extract hair follicle units from the scalp during hair transplantation. It also offers an advanced hair restoration technology known as NeoGraft.

The company recently announced its latest financial results which show an increase in its total revenue. It is focused on making progress in product development, having received clearance to market some of its products in the U.S. and Canada. This may help extend consumer reach and bring in more revenue into the company.

Venus Concept Inc. (VERO), closed Thursday's trading session at $0.31, up 16.9811%, on 587,647 volume. The average volume for the last 3 months is 43,139 and the stock's 52-week low/high is $0.15/$2.21.

Celcuity Inc. (CELC)

MarketBeat, InvestorPlace, TradersPro, QualityStocks, MarketClub Analysis, BUYINS.NET, StreetInsider, StockMarketWatch, Profitable Trader Authority, PennyStockScholar, PennyStockProphet and OTCtipReporter reported earlier on Celcuity Inc. (CELC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology firm that is engaged in developing molecularly targeted therapies for patients with cancer.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in January 2012 by Lance G. Laing and Brian F. Sullivan. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to a license agreement with Pfizer Inc., which entails developing and commercializing rights to Gedatolisib. It designs technology to identify abnormal cellular processes in order to treat cancer.

The enterprise has designed a diagnostic platform dubbed CELsignia, which uses living tumor cells from a patient to identify a particular abnormal cellular process driving an individual’s cancer and the associated targeted therapy for the treatment. It also develops a qualitative lab-developed test dubbed the CELsignia MP test, which measures P13K, c-Met and HER2 signaling activity in ovarian and breast cancer tumor cells. Its drug candidates include a formulation dubbed Gedatolisib, which targets different class I P13K isoforms and mammalian targets of rapamycin. It is focused on treating patients with HER2-negative, hormone receptor positive and metastatic or advanced breast cancers.

The firm is focused on submitting its Gedatolisib formulation in the future to the FDA for a New Drug Application in treating a broad patient population. The success and approval of this drug will bring in additional revenues as well as investments into the firm, which will be good for its growth.

Celcuity Inc. (CELC), closed Thursday's trading session at $9.54, up 26.3576%, on 43,689 volume. The average volume for the last 3 months is 40,256 and the stock's 52-week low/high is $4.81/$14.78.

Hempacco Co. (HPCO)

RedChip, The Stock Dork and QualityStocks reported earlier on Hempacco Co. (HPCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hempacco Co. Inc. (NASDAQ: HPCO) is a company involved in the manufacture and sale of smokable hemp and herb products.

The firm has its headquarters in San Diego, California and was incorporated in 2019, on April 1st by Jorge Olson and Sandro Piancone. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers in the United States.

The company is focused on disrupting tobacco by manufacturing and selling tobacco-free and nicotine-free alternatives to traditional cigarettes, both under its own name and white label products for clients. Its operating segments include intellectual property licensing, private label manufacturing and sales, and the development and sale of in-house brands using patented counter displays.

The enterprise uses a proprietary, patented spraying technology for terpene infusion and patent-pending flavored filter infusion technology to manufacture its hemp and herb-based smokable alternatives. Its hemp-based cigarettes and hempbar liquor-flavored infused hemp smokables are provided under the The Real Stuff Smokables brand. The enterprise also provides research and development on hemp, hemp smokables and the materials required to produce these products. Its in-house brands are sold in roughly 200 retail locations found in San Diego. It also owns about 600 kiosk vending machines.

The firm recently entered into a new joint venture with Sonora Paper Company, involving the manufacture and marketing of hemp blunt wraps, tubes and smoking cones. This move will not only generate additional revenues for the firm but also extend its consumer reach.

Hempacco Co. (HPCO), closed Thursday's trading session at $1.32, off by 2.9412%, on 40,256 volume. The average volume for the last 3 months is 51,809 and the stock's 52-week low/high is $1.31/$41.80.

Intelligent Living Application Group (ILAG)

MarketClub Analysis and INO Market Report reported earlier on Intelligent Living Application Group (ILAG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Intelligent Living Application Group Inc. (NASDAQ: ILAG) is a holding firm that is focused on manufacturing and selling mechanical locksets.

The firm has its headquarters in Kwai Chung, Hong Kong and was incorporated in 1981 by Po Wang Hui. It operates as part of the building products and equipment industry, under the industrials sector. The firm serves consumers around the globe, with a primary focus on consumers in Australia, China, Canada and the United States.

The company’s aim is to make life safer and smarter by designing and producing affordable, high-quality locksets and smart security systems. It is committed to bringing sound and intelligent thoughts, as well as good ideas together to form practicable solutions that offer a smarter, safer and better living space for its home users.

The enterprise manufactures mechanical locksets such as passage locksets, deadbolts, entry locksets and privacy locksets, among others, for both indoor uses as well as for the outdoors , like main entrances and gates. It also develops and sells smart locks. The enterprise distributes its range of original design manufacturer door locksets to different customer segments with classic to contemporary looks, functions and colors, within both domestic and overseas markets.

The firm recently announced its latest financial results, which show significant increases in its revenues and gross profits. It remains focused on operating more efficiently in a bid to improve its margins and position itself for future growth, which will in turn help create shareholder value.

Intelligent Living Application Group (ILAG), closed Thursday's trading session at $1.59, up 5.298%, on 51,809 volume. The average volume for the last 3 months is 6,558 and the stock's 52-week low/high is $1.4906/$26.40.

biote Corp. (BTMD)

MarketBeat reported earlier on biote Corp. (BTMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

biote Corp (NASDAQ: BTMD) is a medical practice-building business that is engaged in the provision of precision and preventive medicines, within the hormone optimization space.

The firm has its headquarters in Irvine, Texas and was incorporated in 2012. It operates as part of the medical care facilities industry, under the healthcare sector. The firm serves consumers across the globe.

The woman-led company offers a comprehensive, end-to-end platform with necessary components that allow practitioners to establish, build, and successfully operate hormone optimization centers to treat patients appropriate for therapy using personalized solutions. It also trains practitioners how to identify and treat early indicators of hormone-related aging conditions. This is in addition to providing digital and point-of-care marketing support.

The enterprise also offers a platform for Biote-certified practitioners to optimize imbalances in their patients’ hormone, mineral and vitamin levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. This is in addition to selling sterile pellet insertion kits for women and men; and Biote-branded dietary supplements. As of December 2022, the enterprise had about 5300 practitioners in its network of medical providers who are Biote certified to administer bioidentical hormone therapy.

The company recently released its latest financial results, which show increases in its revenues. It remains focused on expanding its sales force and building its brand, which will open it up to new growth opportunities while increasing awareness on the benefits of hormone optimization therapies. This is in addition to generating value for its shareholders.

biote Corp. (BTMD), closed Thursday's trading session at $4.225, off by 1.5152%, on 6,582 volume. The average volume for the last 3 months is 2.664M and the stock's 52-week low/high is $2.00/$10.525.

Shuttle Pharmaceuticals (SHPH)

QualityStocks, The Stock Dork and Schaeffer's reported earlier on Shuttle Pharmaceuticals (SHPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is a specialty pharmaceutical firm focused on discovering, developing and commercializing drugs to protect normal tissues from radiation injury and sensitize cancers to radiation therapy.

The firm has its headquarters in Rockville, Maryland and was incorporated in 2012. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers around the globe.

The company leverages its proprietary technology to develop new treatments that have been designed to cure cancer. Its primary objective is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy, that is, radiation therapy, surgery, immunotherapy and chemotherapy. The company mainly operates through its Shuttle Pharmaceuticals Inc. subsidiary.

The enterprise’s pipeline comprises of radiation sensitizers and immunotherapy-assisting candidates. They include an injectable hypoxic cell radiation sensitizer dubbed Doranidazole, which has been developed to treat lung, liver and pancreatic cancers; and an oral halogenated pyrimidine known as Ropidoxuridine, for the treatment of patients with soft tissue sarcomas and brain tumors. It also advances pre-clinical stage dual functional ataxia-telangiectasia mutated/histone deacetylase (ATM/HDAC) targeting candidate drugs, which protect normal cells by activating the ATM gene product and the deoxyribonucleic acid (DNA) damage response pathway.

The company, which recently entered into an agreement with TCG GreenChem Inc. that would entail the manufacture of Ropidoxuridine, announced its latest financial results, with its CEO noting that they remained committed to advancing its candidates as they worked towards delivering new and innovative treatments to cancer patients.

Shuttle Pharmaceuticals (SHPH), closed Thursday's trading session at $2.71, up 24.8848%, on 2,664,295 volume. The average volume for the last 3 months is 43,028 and the stock's 52-week low/high is $1.35/$126.26.

ZeroFox Holdings (ZFOX)

MarketBeat reported earlier on ZeroFox Holdings (ZFOX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ZeroFox Holdings Inc. (NASDAQ: ZFOX) is an enterprise cybersecurity Software-as-a-Service firm that is engaged in the provision of solutions that address the full lifecycle of external cyber risks and threats.

The firm has its headquarters in Baltimore, Maryland and was incorporated in 2013. It operates as part of the software-infrastructure industry, under the technology sector. The firm serves consumers around the globe.

The company has designed an AI-based analysis engine dubbed the ZeroFox Platform, which identifies and remediates credential compromise, targeted phishing attacks, data exfiltration, executive and location threats, brand hijacking, and more. The components of its platform include ZeroFox Predict, ZeroFox Protect, ZeroFox Detect, ZeroFox Disrupt and ZeroFox Response.

The enterprise’s ZeroFox Predict is a threat intelligence solution that allows consumers to directly search across a data lake of global threat indicators, exploits, tactics, adversary intelligence, vulnerabilities, and security tools; while ZeroFox Protect allows organizations to configure protective capabilities to identify and protect their external assets. Its ZeroFox Detect component affords consumers real-time asset and vulnerability awareness for their external-facing internet digital footprint; while ZeroFox Disrupt can be used to report, block, and take down an attack's core components across the internet. The enterprise’s ZeroFox Response component allows organizations to provide the level of support necessary to respond to external attacks, incidents, data loss or exfiltration, or potential breaches.

The firm, which recently launched a new disruption service dubbed PII Removal, remains focused on extending its reach in the Middle East and Africa. This will positively influence investments and revenues into the firm while also bolstering its overall growth.

ZeroFox Holdings (ZFOX), closed Thursday's trading session at $3.94, up 5.914%, on 44,449 volume. The average volume for the last 3 months is 9.5M and the stock's 52-week low/high is $3.26/$15.65.

Nikola Corporation (NKLA)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, QualityStocks, The Street, MarketBeat, Kiplinger Today, Trades Of The Day, StreetInsider, Daily Trade Alert, The Online Investor, Zacks, Early Bird, Cabot Wealth, Louis Navellier, Wealth Insider Alert, CNBC Breaking News, MarketTamer, Outsider Club, StockMarketWatch, Daily Profit and Investopedia reported earlier on Nikola Corporation (NKLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Uber has established a goal to transition to fully electric cars in Europe by the year 2030 and globally a decade later. To realize this, all of Uber’s independent contractors must trade in their fuel cars for greener alternatives. Uber therefore has seven years to significantly restructure the vehicle configuration in its European operations, where currently less than one in 10 of its vehicles run on electricity.

While some Uber drivers have welcomed the change, others are hesitant to make the switch because of the drawbacks associated with electric vehicles, which include higher initial costs, concerns about inadequate charging stations, and the prolonged time required to charge the car when fueling only takes a short time.

While speaking to EURACTIV, Chris Hook described this reluctance as a normal reaction toward this latest technology. However, he was optimistic that response will be positive once the transition is completed and drivers have the opportunity to drive electric vehicles.

According to Hook, purchasing a vehicle is a significant financial decision for many people, and switching won’t be simple, even if people are persuaded to do so because of the benefits of a healthy environment. Therefore, in order to lower the initial costs of buying and renting an electric vehicle, Uber has entered into agreements with car manufacturers Stellantis, Kia, Hyundai and Nissan to lower their rates on electric vehicles. Uber has also collaborated with BP in the UK and France’s Total Energy companies to install charging stations. This will provide drivers with more affordable payment plans.

According to Hook, these agreements are required so that going electric “makes financial sense” for the drivers. In order to allay concerns regarding the technicalities of the EV range, Uber has assigned EV ambassadors across cities throughout Europe who volunteer to educate drivers based on their experiences.

Hook argues that the early versions of EVs could not match the style of Uber riders; for instance, the 30 kWh batteries did not work well in terms of daily range. But once 62 kWh batteries were developed, things changed. Today, 95% of Uber drivers can drive longer distances without worrying about running out of charge. Hook clarified that in order for a driver to enjoy this, they must fully charge their vehicles and be able to recharge as needed.

Even though Uber intends to make the complete switch to electric vehicles advantageous to the drivers as the year 2030 draws closer, it appears that not all vehicles will qualify to operate, and thus it is obvious that Uber will have to impose certain criteria in order to distinguish between those who qualify and those who do not.

According to Hook, there should be a significant number of fully electric vehicles as the year 2030 draws closer; otherwise, their efforts could have been for nothing.

As more corporate entities such as Uber switch to EVs, a bigger market will quickly open up for all industry players, including Nikola Corporation (NASDAQ: NKLA), as ordinary motorists follow the lead of the corporates.

Nikola Corporation (NKLA), closed Thursday's trading session at $2.38, off by 1.2448%, on 9,562,847 volume. The average volume for the last 3 months is 348,812 and the stock's 52-week low/high is $2.27/$12.14.

Arch Resources Inc. (ARCH)

InvestorPlace, MarketBeat, Zacks, The Online Investor, QualityStocks, MarketClub Analysis, TradersPro, Kiplinger Today, The Street, Schaeffer's, Daily Wealth, StreetAuthority Daily, StreetInsider, Trades Of The Day, Barchart, Uncommon Wisdom, InvestorGuide, Investing Daily, FreeRealTime and Daily Trade Alert reported earlier on Arch Resources Inc. (ARCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Indonesia plans to continue building coal plants, despite its multibillion dollar deal to transition to the use of clean energy. The deal, called the Just Energy Transition Partnership (JEPT), was signed last month at the G20 summit with the G7 group of industrialized nations, including Norway and Denmark.

Data from 2019 shows that Indonesia was the fifth largest emitter of greenhouse gases globally, trailing behind China, India, the United States and the European Union as a whole. Experts believe that the country’s emissions mainly come from deforestation and coal burning, which generates more than 60% of Indonesia’s electricity.

Indonesia’s primary objective, under the deal, was to cap its carbon dioxide emissions from the energy sector by 2030, seven years earlier than its initial target. The country also aimed to generate more than 30% of its power from renewable sources by 2030.

Activists argue that building new fossil fuel-powered plants may cause the deal to collapse before anything is actualized. They believe that not setting a clear deadline for when Indonesia will put a stop to the construction of new coal plants will make it hard to decarbonize the country’s electricity system and, in turn, increase the partnership‘s risk of failure.

The country’s government plans to allow new plants with a total capacity of 13 GW to be built. The plan to do so is stipulated in Indonesia’s 2021–2030 energy plan.

Earlier this year, President Joko Widodo issued a regulation that permitted the construction of captive coal plants, which would not feed into the grid but only supply specific industries with power.

This move does not align with the partnership, as reiterated in a joint statement made by JEPT partners, who revealed that they plan to hinder the development of these coal plants. In the statement, the partners also highlight that the energy partnership is dependent on no construction of coal plants, where zero-emissions, affordable, timely and reliable alternatives are available.

They also request that a strategy to avoid new coal plants be developed, one which can identify investments in various renewable energies as alternatives to the fossil fuel. Furthermore, the donor group emphasized that if a certain captive coal plant project set in Borneo, Indonesia, made headway, the deal would be withdrawn.

It is expected that as Indonesia’s economy grows, emissions from its power sector will continue to increase. At the moment, the country has the largest economy in southeast Asia and the 17th largest globally, based on nominal GDP.

The continuing sanctioning of new coal plants by Indonesia shows just how the demand for energy is at the moment, and coal producers such as Arch Resources Inc. (NYSE: ARCH) are having to work double time to satisfy the orders intended to see different countries through this winter and possibly beyond.

Arch Resources Inc. (ARCH), closed Thursday's trading session at $146.12, off by 1.7615%, on 353,593 volume. The average volume for the last 3 months is 881,542 and the stock's 52-week low/high is $80.18/$183.53.

atai Life Sciences N.V. (ATAI)

StockMarketWatch, MarketBeat, QualityStocks and TradersPro reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Interest in psychedelic-assisted therapies has blown up over the past couple of years amid surging interest in psychedelic medications across the mainstream and scientific communities. As America’s mental health crisis has grown, there has been increased interest in alternative treatments that do not have the usual side effects associated with typical pharmaceutical drugs.

Psychedelics, long enjoyed in certain circles for their hallucinogenic effects, are now being studied for their potential mental health benefits. Early research reveals that drugs such as psilocybin and ketamine can effectively treat mental health conditions, including depression, PTSD and eating disorders, with minimal side effects.

Now, the pharmaceutical industry and other investors are pouring millions of dollars into researching and developing psychedelic-assisted therapies for the masses. With the psychedelics drug market predicted to be worth a whopping $10.75 billion by the year 2027, several players have streamed into the industry to try and gain a foothold while it is still in its infancy.

Dr. Prash Puspanathan, a psychiatrist with extensive psychedelic research experience, and scientist Agnieszka Sekula are looking to make their mark on the fledgling industry by integrating virtual reality (VR) into the psychedelic treatment process. This technology is designed to help patients integrate the insights and realizations they made during their psychedelic trip into their everyday lives.

Although everyone who undergoes psychedelic-assisted therapy has their own unique experiences while under the influence of the drug, they often have profound emotions and insights as the hallucinogenic effects begin to wear off. Psychedelic Integration, which is the next step of treatment after taking a prescribed dose of psilocybin or ketamine, involves recalling and interpreting these insights in a way that allows the patient to integrate them into their life.

However, these profound realizations can be difficult to express in words, and they often begin to slip away as soon as the psychedelic wears off the same way dreams slip from our memories when we wake up. Puspanathan and Sekula have developed a software called AnchoringVR that can be used to enhance integration by creating immersive settings where patients can use visual and audio elements to create their own worlds.

This VR treatment is offered toward the end of psychedelic-assisted therapies, with the patients who have used Anchoring VR doing so for around 45 minutes. The short recording they create during their VR sessions is then played during each integration session in the company of their therapists to help solidify their insights.

Puspanathan said that patients are more likely to speak comfortably and freely when they are “encased within a cocoon” that came from the recesses of their minds.

It would be interesting to see how this VR technology performs when paired with the drugs under development by startups such as atai Life Sciences N.V. (NASDAQ: ATAI) during clinical trials.

atai Life Sciences N.V. (ATAI), closed Thursday's trading session at $3.29, up 3.4591%, on 883,540 volume. The average volume for the last 3 months is 203 and the stock's 52-week low/high is $2.60/$11.8196.

The QualityStocks Company Corner

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Researchers have discovered that crossword puzzles help to better sharpen memory in older individuals suffering from mild cognitive impairment, incomparison to computer games. While crossword puzzles are popularlyused, no research has systematically studied them and theirassociation with mild cognitive impairment until now. Mild cognitive impairment is known to heighten the risk of an individual developingdementia. The study was led by Professor D.P. Devenand of ColumbiaUniversity and Professor Murali Doraiswamy, director of theNeurocognitive Disorders Program at Duke University School ofMedicine. For their study, the researchers recruited more than 100participants suffering from mild cognitive impairment, a majorityof who were around 71 years of age. They were all required tofinish 12 weeks of either cognitive games training or computerized crossword puzzle training. Once this was done, eachof the participants would undergo six booster sessions. Meanwhile,the field of pediatric and adult malignant tumor research is alsoregistering some interesting developments. For example, a number ofentities such as QSAM Biosciences Inc. (OTCQB: QSAM) are reporting exciting findings, including coming up with targeteddrugs with minimal damage during radiation therapy.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Thursday's trading session at $5.15, up 3%, on 203 volume. The average volume for the last 3 months is 7,357 and the stock's 52-week low/high is $3.50/$14.00.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orallydelivered fat-soluble active molecules and drugs, has, sinceinception, been committed to addressing severe unmet patient needs.Hypertension has been one of its main focus areas. “Lexariacontinues to move forward, most recently with the success in itslatest human clinical study, HYPER-H21-4. The study may be thefirst to evidence a sustained drop in blood pressure in normallyactive patients following multiple weeks of oral cannabidiol(‘CBD’) therapy using the company’s patented DehydraTECH(TM)technology,” reads a recent article. “Since Lexaria begandeveloping DehydraTECH in 2014, it has continued to strengthen andbroaden the technology, exploring various areas including but notlimited to the oral administration of antivirals, cannabinoids,vitamins, nicotine, and PDE5 inhibitors. In early 2021, it begandosing in its first human clinical study that assessed itsDehydraTECH-enabled CBD capsule formulation. This would lay thegroundwork for subsequent studies while also bolstering thecompany’s growing list of patents, which currently stands at 27,spread across the world, including the use of DehydraTECH-processedCBD for the treatment of heart disease.”

To view the full article, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.92, up 0.689655%, on 7,395 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $14.00/$.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, today announced additional details around its plans for theupcoming CES 2023, slated to be held in Las Vegas, Nevada, fromJan. 5-8, 2023. According to the update, Cepton’s booth (No. 5553,LVCC – West Hall) will feature a Chevy Silverado and a Ford F-150equipped with the company’s latest vehicle integration solutions.“Developing cutting-edge lidar technology is one thing, but makingit usable for consumer vehicles is another,” said Cepton’s CEO andCo-Founder Dr. Jun Pei. “Integrating lidars into everyday passengercars is more challenging than it seems, with many factors that needto be taken into consideration, such as performance, sensor datafusion, system maintenance and vehicle design. This year at CES, weare thrilled to showcase the innovative solutions we’ve developedto address these challenges as we continue to build capable,reliable, embeddable and affordable lidar solutions for variousassisted and automated driving scenarios.”

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Thursday's trading session at $1.35, up 5.4688%, on 149,043 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

U.S. President Joe Biden made history when he enacted the cannabis research bill and signed it into law on Nov. 2, 2022.The law now waits for 60 days for the attorney general to eitherapprove it or ask for supplementary information from the originatorof the bill. This new law opens the gates for further extensiveresearch on marijuana to be done. The use of cannabis is prohibitedfederally in the United States except for FDA-approved research.Specific states have, however, enacted legislation permitting theplant or its derivatives for research, medical, industrial and orrecreational purposes. President Biden still stands opposed to thelegalization of cannabis. However, he has campaigned on severalplatforms for reforms of marijuana, including promoting research,decriminalization, more modest reforms to marijuana laws andrescheduling cannabis under the Controlled Substances Act (CSA). This also comes hot on the heels of a mass pardon for Americans whohave been convicted for being in possession of cannabis. Thisclemency has been viewed by the White House as one of the top accomplishments of the president. The Department of Health and Human Services iskeen on learning about the health benefits versus the risks ofcannabis. And, as more people take up the home cultivation ofmedical marijuana, entities that focus on making indoor cultivationequipment, such as Advanced Container Technologies Inc. (OTC: ACTX), are likely to expand their footprint across the nation.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.45, up 20.016%, on 432 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.42.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest (CSE: HEAT) (OTCQB: HLRTF) is a clean tech company developing transformative power conversiontechnologies and control system solutions for next-generationelectrical systems. The company today announced that, withcompletion of its first Zero Voltage Switching (“ZVS”) invertercommercial prototype, it is accelerating its development activitiesaround grid-tied power conversion technologies. Hillcrest isdeveloping the necessary firmware and hardware to deploy its ZVSinverter technology into various applications, including renewableenergy generation, storage, vehicle-to-everything (“V2X”) and EVcharging infrastructure. “Our ZVS inverter technology isintentionally designed to be decoupled from the power controlsystem, making our firmware agnostic to specific applications,allowing us to move quickly to adapt our technology to any motor orgrid application,” said Chief Technology Officer Ari Berger. “Withthe completion of our 800-volt, 250-kilowatt traction invertercommercial prototype, we’ve set the foundation to facilitate ourentry into grid-tied applications such as renewable energygeneration and storage, as well as e-mobility charging.”

To view the full press release, visit

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Thursday's trading session at $0.0786, up 4.6605%, on 10,204 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.072/$0.1724.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • Miami-based REZYFi is a mortgage lender working withtraditional loans but focusing particular attention on unbankedmarket sectors such as the cannabis industry and those propertycompanies that provide leases to those sectors
  • The loan origination industry appears to be experiencing a newround of greening in reversal of the year’s difficulties
  • In the wake of positive CPI data last month, analysts arebeginning to anticipate a greening of mortgage lending ratesonce inflationary pressures are reduced, making it easier forcompanies to obtain loans for their projects

REZYFi is positioned as the first cannabis mortgage banker in the UnitedStates. With most traditional lenders reticent to serve thestate-licensed cannabis industry, REZYFi stands distinct. “REZYFiservices the needs of both traditional and non-traditionalconsumers and businesses. The company is targeting markets thatinclude licensed and permitted cannabis companies, owners of realestate who lease to cannabis companies, and companies andindividual homeowners seeking a variety of real estate-relatedfirst and additional mortgage-based financing and project-specificfinancings, such as solar installations and real estate developmentprojects,” a recent article reads. “REZYFi operates under twowholly owned subsidiaries – REZYFi Lending and ResMac Inc. REZYFiLending primarily addresses emerging real estate-related financingopportunities. ResMac is the company’s traditional mortgageorigination, correspondent and servicing operation. As a whole,REZYFi is using its corporate strengths as a foundation fordiversifying its approach to capitalize on growth in multipleverticals in the years to come.”

To view the full article, visit

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is a business focused on enabling consumers to reclaim theironline information and monetize it. “Reklaim has been at theforefront of the battle to assist and empower users to establishownership over personal data, which has, in many cases, beencirculating in the market unbeknownst to them. The company’sactions have encountered renewed impetus given the increased focuson protecting data privacy from the Federal Trade Commission(‘FTC’) and its ongoing initiatives toward making online privacy apriority,” a recent article reads. “With Reklaim, not only areconsumers able to unlock the online data collected on them, theyare able to preclude the data from leaking from their devices inthe first place – the latter scenario being one which has long beenexploited by search engines, social media platforms and online databrokers alike. Rather, should they wish, consumers are empowered tomonetize their data, gaining compensation in return for providingthird-party businesses with insights drawn from their onlinebehavior.”

To view the full article, visit

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online ( and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Thursday's trading session at $0.02393, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0223/$0.345.

Recent News

Data443 Risk Mitigation Inc. (OTC: ATDS)

The QualityStocks Daily Newsletter would like to spotlight Data443 Risk Mitigation Inc. (OTC: ATDS).

Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company for ALL THINGS DATASECURITY(TM), is committed to organizing the world’s information byidentifying and protecting all sensitive data regardless oflocation, platform or format. “Data443 derives revenue primarilyfrom contracts for subscriptions to access its SaaS platforms andancillary services provided in connection with its subscriptionservices,” a recent article reads. “[Its] offerings include: DataIdentification Manager [provides the ability to automaticallyinventory all data repositories, classify and tag all data, andenable global search and discovery]; Data Placement Manager[quickly transfers sensitive data over any public or privatenetwork]; Data Archive Manager [designed to handle and manage alltypes of privacy requests across cloud, on-premises, and hybridenvironments]; Data Hound(TM) [a data discovery, classification andcapture toolset]; Ransomware Recovery Manager [actively recoversthe device, operating system and data with a simple reboot]; AccessControl Manager [provides user ID and passwordless access toquickly enable trust across an organization’s entire ecosystem];Global Privacy Manager [provides organizations one comprehensiveview, for all privacy requirements, across all enterprise data, allat once]; and Sensitive Content Manager [a security-centriccollaboration service].”

To view the full article, visit

Data443 Risk Mitigation Inc. (OTC: ATDS) is a data security and privacy software company for ALL THINGS DATA SECURITY™. The company is committed to organizing the world’s information by identifying and protecting all sensitive data regardless of location, platform or format.

Data443 provides software and services to enable secure data across devices and databases – at rest and in transit – locally, on a network, or in the cloud. With over 10,000 customers in more than 100 countries, Data443 provides a modern approach to data governance and security. The company’s framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies.

Data443 derives revenue primarily from contracts for subscriptions to access its SaaS platforms, and ancillary services provided in connection with its subscription services. In today’s ever-changing environment with unique and complex requirements for data privacy, governance and hybrid workforces, every organization needs to know where all their data is, who has access to it and how sensitive it is. Data443 provides the tools needed to give companies control over their data processing activities, with capabilities for identifying, reporting and migrating or deleting sensitive data.

The company is headquartered in Research Triangle Park, North Carolina.


Focused on data security with a privacy-forward methodology, the Data443 product suite delivers solutions designed to securely manage data and data privacy needs on-premises, in the cloud and in hybrid environments. Offerings include:

  • Data Identification Manager reduces risk by shining a light on dark data across cloud, on-premises and hybrid environments. From a centralized dashboard, Data Identification Manager provides the ability to automatically inventory all data repositories, classify and tag all data, and enable global search and discovery – all through an agentless deployment.
  • Data Placement Manager quickly and securely transfers sensitive data over any public or private network. Available as an HP Nonstop server-based application and for Windows, Linux or any public cloud provider, Data Placement Manager enables the scheduling, routing, formatting and transfer of business-critical data.
  • Data Archive Manager is an “all information, anywhere” archiving solution designed to handle and manage all types of privacy requests across cloud, on-premises and hybrid environments. With over 15 years operational history and hundreds of clients managing millions of mailboxes, the platform is purpose-built for information archiving, retention and privacy request management.
  • Data Hound™ is a data discovery, classification and capture toolset that enables organizations to perform quick scans, detailed reporting and subsequent data actions based on policy.
  • Ransomware Recovery Manager is the only industry solution that actively recovers the device, operating system and data with a simple reboot. Using patented, proven technology, the product produces 100% effectiveness for the whole device and datasets.
  • Access Control Manager provides user ID and passwordless access to quickly enable trust across an organization’s entire ecosystem. Its unique architecture allows it to leverage multiple distributed authoritative sources to understand and resolve a typical access request – with the ability to enable or deny the action on the fly.
  • Global Privacy Manager provides organizations one comprehensive view, for all privacy requirements, across all enterprise data, all at once. This unmatched visibility into an organization’s data assets ensures that all private and sensitive data can be identified and protected and that enterprises can obey all relevant privacy laws in any jurisdiction.
  • Sensitive Content Manager is a security-centric collaboration service designed to give organizations the tools needed for successful content sharing, collaboration and safe distribution with full enterprise management in mind. With a continuous sync feature, encrypted data is automatically downloaded and updated in real time – regardless of location – ensuring that users have the most accurate data available.

Market Outlook

A report from Allied Market Research estimates that the global data security market was worth about $19 billion in 2021 and is projected to reach a value of $54.23 billion by 2027. That represents a CAGR of more than 18% for the forecast period, making data security one of the hottest areas within IT.

Separately, Fortune Business Insights estimates the global data privacy software market is valued at $2.36 billion in 2022 and projects it will grow to $25.85 billion by 2029. That represents a CAGR of 40.8% over the forecast period.

Management Team

Jason Remillard is President, CEO and Founder of Data443. He is responsible for overseeing global expansion, management, execution and corporate development. With over 25 years in global enterprise and B2C software sales and marketing, he brings deep leadership and technical experience, having spent previous time at Fortune 500 companies such as Deutsche Bank, TD Bank, IBM & Merrill Lynch.

Greg McCraw is CFO at Data443. He has over 25 years of experience helping businesses strengthen their accounting and finance operations. He previously served as Vice President of Finance for a dental services organization active in acquisitions, and, prior to that, he was managing director of a boutique accounting and finance consulting firm advising Fortune 500 clients in pharmaceutical, financial services, and private equity sectors on how to execute on regulatory and compliance solutions.

Bennett Pursell is Data443’s Chief Technology Officer. He has over 20 years of experience in IT architecture, security governance and systems integration. Prior to his role at Data443, he served as Head of Technology Architecture at Moody’s Investor Services and was Vice President and Technical Architect of Cloud Computing at Deutsche Bank, along with a host of technical and project management roles dating back to 2006, after starting his career as a web developer with a few startups and running research labs.

Kirill Kashigin is Chief Software Architect at Data443. He leads the development and quality teams, and serves as technical adviser and subject matter expert, bringing vast technical knowledge on privacy management and data security. Formerly the CTO of FileFacets, he has nearly 20 years in development of high-performance systems and deployment.

Data443 Risk Mitigation Inc. (OTC: ATDS), closed Thursday's trading session at $1, off by 13.0435%, on 13,102 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.85/$6.99.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

Services provided by SideChannel include CISO, vCPO, riskassessment and management, plus cybersecurity compliance

SideChannel announced preliminary revenue reached $4.6 to $4.8million for the fiscal year ending September 30, 2022, representinga significant YOY increase

The global cybersecurity market size is expected to grow from anestimated $173.5 billion in 2022 to $266.2 billion by 2027, growingat a CAGR of 8.9% during the forecast period

SideChannel Inc. (OTCQB: SDCH) CEO Brian Haugli is featured in a recent Proactive interviewtitled “SideChannel ‘moving upstream’ in cybersecurity.” Accordingto the announcement, Haugli discusses several key things during theinterview, including how the three-year-old company’s strategy hasevolved and the niche he believes SideChannel fills in thecybersecurity space. He also talks about the company’s promisingfuture and what investors can expect from the company movingforward. To view the full article, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Thursday's trading session at $0.1111, off by 7.4167%, on 4,140 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$0.18.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

New research has found that the legalization of medical cannabishas been linked to a reduction in the use and prescription of opioids for patients with cancer. The researchinvolved a cross-section analysis of data on insurance claims frommore than 38,000 individuals who had recently been diagnosed withcancer. The analysis included 34 states and was carried out byresearchers at the University of Texas, Harvard University, AlbertEinstein College of Medicine and Weill Medical College of CornellUniversity. The researchers’ objective was to examine how theexistence of more cannabis dispensaries influenced opioidprescription. Researchers discovered that medical marijuanalegalization implemented in the period between 2012 and 2017 wasassociated with a 5.5% to 19.2 % relative reduction in the rate atwhich opioids were dispensed. The researchers stated that medicalcannabis could be serving as an opioid drug substitute among somepatients who were undergoing treatment for cancer. Many companies,such as India Globalization Capital Inc. (NYSE American: IGC), are developing cannabinoid-based formulations focused onalleviating chronic pain, so the number of cancer patients usingopioids is likely to drop even further once these novel drugsbecome available.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Thursday's trading session at $0.3951, off by 2.7805%, on 125,719 volume. The average volume for the last 3 months is 122,069 and the stock's 52-week low/high is $0.37/$1.29.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announcedthat Donald Borthwick, previously head of western sales for Ford,will be its new vice president of commercial sales. With more thantwo decades of commercial vehicle sales experience with Ford,Borthwick has amassed an impressive track record. He grew thecompany’s west region commercial vehicle sales by 18% during histime there while also achieving regional volume and marginleadership annually. He acquired and developed strategicrelationships with key, high-volume accounts from an array ofsectors, including consumer retail, food service and packagedelivery while also securing a primary vehicle supplierrelationship with a leading last-mile delivery company. He also hascultivated early EV adopter customers, resulting in strategicearly-stage EV system-fill orders. “Don is a highly skilled andrespected sales leader and will play a key role in establishingMullen as a leader in the commercial EV category,” said Mullen CEOand chair David Michery in the press release.

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.1906, off by 0.521921%, on 138,629,832 volume. The average volume for the last 3 months is 136.092M and the stock's 52-week low/high is $0.18/$7.50.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope’s (NASDAQ: KSCP) CEO and Chairman William Santana Li recently appeared on The Shrimp Tank, a podcast series featuring proven entrepreneurs and businessleaders discussing how to start, grow and run a successfulbusiness. Li joined the program’s hosts, Lee Heisman and TedJenkin, to discuss Knightscope’s Machine-as-a -Service (“MaaS”)business model and how the company is using it to improve securitywhile streamlining costs.

“Technology can have a massively positive impact on society. Crimehas a $2 trillion negative economic impact on the U.S. every singleyear. What we’ve been doing at Knightscope for almost 10 years isbuilding profound new technology to address a recurring societalproblem with a recurring revenue business model, and we built thesecrazy autonomous security robots that are now patrolling across thecountry,” Li said.

“We have a Machine-as-a-Service business model. We don’t sellhardware or software; everything is basically included – datastorage, telecom, decals, shipping, maintenance, support,everything. It can be as high as $9/hour for our technology,indoors or outdoors, or as low as $0.75/hour… If you compare ourofferings to unarmed security guards at $15-$30/hour or an armed,off-duty law enforcement officer at around $85/hour, our modelpresents a massive change and a massive opportunity.”

To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $1.98, off by 3.4146%, on 343,469 volume. The average volume for the last 3 months is 343,111 and the stock's 52-week low/high is $1.84/$27.50.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.